Australia's Telix Pharmaceuticals slides on sequential fall in quarterly revenue
Yesterday 03:56
BUZZ-Australia's Telix Pharmaceuticals slides on sequential fall in quarterly revenue ** Shares of Australia's Telix Pharmaceuticals TLX.AX fall 7.6% to A$14.56, hitting their lowest level since August 5
** The radiopharmaceutical company reported a 1% sequential fall in group revenue for the third quarter to $235 million, though this was an increase compared to last year
** Revenue from its biggest segment precision medicine was stagnant, compared with previous quarter at $201 million
** "We expect some seasonality and our 2H forecasts imply 4Q will rise again, against the backdrop of a maturing market in existing indications," says Citi
** Telix stock up over 30%, YTD
(Reporting by Shruti Agarwal in Bengaluru)
Recent news on Telix Pharmaceuticals
See all newsJefferies cuts price target on Telix Pharmaceuticals following quarterly update
Australia's Telix Pharmaceuticals slides on sequential fall in quarterly revenue
Brief: Telix Pharmaceuticals Limited Reports Qtrly Group Revenue Of $245 Million
Education Agreement To Advance Psma-Informed Prostate Care
Australia's Telix rises after dosing first US patients with brain cancer imaging drug